{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:23:59Z","timestamp":1792225439165,"version":"4.4.0"},"reference-count":67,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several clinical trials have demonstrated that some patients with chronic myeloid leukemia in chronic phase (CML\u2010CP) who achieve sustained deep molecular responses on tyrosine kinase inhibitor (TKI) therapy can safely suspend therapy and attempt treatment\u2010free remission (TFR). Many TFR studies to date have enrolled imatinib\u2010treated patients; however, the feasibility of TFR following nilotinib or dasatinib has also been demonstrated. In this review, we discuss available data from TFR trials and what these data reveal about the molecular biology of TFR. With an increasing number of ongoing TFR clinical trials, TFR may become an achievable goal for patients with CML\u2010CP.<\/jats:p>","DOI":"10.1002\/cam4.801","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T15:43:12Z","timestamp":1467387792000},"page":"2398-2411","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Deep molecular responses for treatment\u2010free remission in chronic myeloid leukemia"],"prefix":"10.1002","volume":"5","author":[{"given":"St\u00e9phanie","family":"Dulucq","sequence":"first","affiliation":[{"name":"Laboratoire d'H\u00e9matologie Centre Hospitalier Universitaire de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois\u2010Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"Bergoni\u00e9 Cancer Institute INSERM Unit 916 University of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood.V124.21.4541.4541","article-title":"Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): long\u2010term follow\u2010up (f\/u) of ENESTnd","volume":"124","author":"Larson R. A.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23560"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011239"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139899"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.654.654"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.V120.21.2788.2788","article-title":"Detailed investigation on characteristics of Japanese patients with chronic phase CML who achieved a durable CMR after discontinuation of imatinib \u2010 an updated result of the keio STIM study","volume":"120","author":"Matsuki E.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"issue":"1","key":"e_1_2_11_14_1","first-page":"LB2440","article-title":"First interim analysis of a pan\u2010european stop trial using standardized molecular criteria: results of the EURO\u2010SKI trial","volume":"99","author":"Saussele S.","year":"2014","journal-title":"Haematologica"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V120.21.916.916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)\u2010chronic myeloid leukemia (CML) patients with stable undetectable BCR\u2010ABL transcripts","volume":"120","author":"Rea D.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V126.23.345.345","article-title":"Long\u2010term follow\u2010up of the french 1 stop imatinib study (STIM1) in chronic myeloid leukemia patients","volume":"126","author":"Etienne G.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1182\/blood.V126.23.4035.4035","article-title":"Around 70% of japanese CML patients could stop imatinib according to A\u2010STIM criteria: the JALSG\u2010STIM213 study","volume":"126","author":"Takahashi N.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_11_20_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology.2016.Chronic Myelogenous Leukemia. V1.2016."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.944973"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-477687"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24397"},{"key":"e_1_2_11_26_1","unstructured":"Tasigna (nilotinib)[package insert].2015.Novartis Pharmaceuticals Corporation East Hanover NJ."},{"key":"e_1_2_11_27_1","unstructured":"Gleevec (imatinib)[package insert].2015.Novartis Pharmaceuticals Corporation East Hanover NJ."},{"key":"e_1_2_11_28_1","unstructured":"Sprycel (dasatinib)[package insert].2015.Bristol\u2010Myers Squibb Company Princeton NJ."},{"key":"e_1_2_11_29_1","unstructured":"Iclusig (ponatinib)[package insert].2014.ARIAD Pharmaceuticals Cambridge MA."},{"key":"e_1_2_11_30_1","unstructured":"Bosulif (bosutinib)[product monograph].2015.Pfizer Canada Inc. Kirkland Quebec Canada."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.151.151"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V122.21.255.255","article-title":"Long term follow\u2010up after imatinib cessation for patients indeep molecular response: the update results of the STIM1 study","volume":"122","author":"Mahon F. X.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood.V124.21.4547.4547","article-title":"Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP) toward treatment\u2010free remission (TFR)","volume":"124","author":"Boquimpani C. M.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1584.1584"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1736"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2159-7"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12258"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-280206"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V124.21.811.811","article-title":"Dasatinib or nilotinib discontinuation in chronic phase (CP)\u2010chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR\u2010ABL transcripts: interim analysis of the STOP 2G\u2010TKI study with a minimum follow\u2010up of 12\u00a0months \u2013 on behalf of the french CML group filmc","volume":"124","author":"Rea D.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V126.23.343.343","article-title":"Mature, adaptive\u2010like CD56DIM\u00a0NK cells in chronic myeloid leukemia patients in treatment free remission","volume":"126","author":"Ilander M.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.V126.23.599.599","article-title":"Frequency of CTLA\u20104 receptor ligand (CD86, B7.2)\u2010positive plasmacytoid dendritic cells predicts risk of disease recurrence after tyrosine\u2010kinase inhibitor discontinuation in chronic myeloid leukemia: results from a prospective substudy of the euroski trial","volume":"126","author":"Burchert A.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.29"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-291641"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.196477"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.217"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08603.x"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095158"},{"issue":"1","key":"e_1_2_11_51_1","first-page":"P228","article-title":"Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: 6\u2010year follow\u2010up of ENESTnd","volume":"100","author":"Hughes T. P.","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544015"},{"key":"e_1_2_11_53_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood.V118.21.603.603","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study","volume":"118","author":"Mahon F. X.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1159\/000440936"},{"key":"e_1_2_11_55_1","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood.V126.23.2775.2775","article-title":"Imatinib suspension and validation study: results at 24\u00a0months","volume":"126","author":"Mori S.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_56_1","unstructured":"ClinicalTrials.gov. Available atwww.clinicaltrials.gov."},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.tps7124"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.6910"},{"key":"e_1_2_11_59_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.V126.23.137.137","article-title":"Osteoarticular pain after discontinuation of tyrosine kinase inhibitors: a French cohort","volume":"126","author":"Berger M. G.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12892"},{"key":"e_1_2_11_61_1","first-page":"856","article-title":"Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)\u2010chronic myeloid leukemia (CML) with undetectable BCR\u2010ABL transcripts for at least 2\u00a0years: preliminary results from immunostim, on behalf of STIM investigators","volume":"122","author":"Rea D.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3320"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1701"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500407996"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-690"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003211"},{"key":"e_1_2_11_67_1","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood.V126.23.4050.4050","article-title":"Rapid achievement of MR4.5 after switching from imatinib (IM) to nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP): preliminary results from ENESTgoal","volume":"126","author":"Ritchie E. K.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_68_1","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1182\/blood.V126.23.4040.4040","article-title":"ENESTpath: a phase III study to assess the effect of nilotinib treatment duration on treatment\u2010free remission in chronic\u2010phase chronic myeloid leukemia patients previously treated with imatinib: interim analysis from the first year of induction phase","volume":"126","author":"Rea D.","year":"2015","journal-title":"Blood"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.801","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.801","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T02:41:38Z","timestamp":1696560098000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/cam4.801"],"URL":"https:\/\/doi.org\/10.1002\/cam4.801","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"2016-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}